- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
Dr Hantel on Environmental and Health Impacts of Decentralizing Cancer Care
August 15, 2024
Video
Andrew Hantel, MD, discusses the environmental and health impacts of decentralizing cancer care in response to high emissions generated by health care.
Dr Ravi on Neoadjuvant ARPIs Prior to Radical Prostatectomy in Prostate Cancer
August 14, 2024
Video
Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.
Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast Cancer
August 13, 2024
Video
Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.
Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?
August 11, 2024
Article
Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.
Dr Steiner on a Microdevice for Evaluating Responses to RCC Treatment
August 09, 2024
Video
Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.
Dr Machaalani on the Interaction Between c-Met and AXL in RCC
August 09, 2024
Video
Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.
Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC
August 08, 2024
Podcast
Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.
Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC
August 08, 2024
Video
Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.
Treatment After Progression on CDK4/6 Inhibitors Requires Careful Consideration in HR+/HER2– mBC
August 08, 2024
Article
Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.
Novel Studies Seek to Optimize HER2+ Breast Cancer Management
August 07, 2024
Article
Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.
Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC
August 07, 2024
Video
Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.
Dana-Farber's Edward Chouchani selected as a Howard Hughes Medical Institute Investigator
August 07, 2024
Article
Edward Chouchani, PhD, of Dana-Farber Cancer Institute, has been named a Howard Hughes Medical Institute Investigator.
Emerging HER2+ Breast Cancer Research Uses Innovative Combinations of Standard Agents
August 06, 2024
Article
Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.
Residual Cancer Burden May Prognosticate Outcomes With Neoadjuvant Therapy in Prostate Cancer
August 06, 2024
Article
Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.
Dr Florez on Addressing Key Gaps in Lung Cancer Care
August 05, 2024
Video
Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.
Dr Rotow on Challenges With Targeting CNS Metastases in Lung Cancer
August 01, 2024
Video
Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.
First-Line Avelumab Maintenance Extends OS in Advanced Urothelial Carcinoma With Low Tumor Burden
July 30, 2024
Article
First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.
Tolaney Details IHC Testing Considerations for HER2-Low TNBC and Data on ADCs
July 29, 2024
Article
Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.
Dr Ravi on the Potential Use of RCB to Inform Neoadjuvant Strategies in High-Risk Prostate Cancer
July 29, 2024
Video
Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.
Tarantino Talks Limitations in HER2-Low Breast Cancer Management, Key Advancements in HER2+/TNBC
July 28, 2024
Article
Paolo Tarantino, MD, discusses current treatment landscapes and looks to the future in HER2-low breast cancer, HER2-positive breast cancer, and TNBC.